Novavax (NVAX) EBIAT (2016 - 2025)
Historic EBIAT for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$202.4 million.
- Novavax's EBIAT fell 6684.17% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 21996.99%. This contributed to the annual value of -$187.5 million for FY2024, which is 6560.02% up from last year.
- Per Novavax's latest filing, its EBIAT stood at -$202.4 million for Q3 2025, which was down 6684.17% from $106.5 million recorded in Q2 2025.
- Novavax's 5-year EBIAT high stood at $518.6 million for Q1 2025, and its period low was -$846.3 million during Q4 2021.
- Moreover, its 5-year median value for EBIAT was -$168.6 million (2022), whereas its average is -$142.7 million.
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 191082.7% in 2021, then soared by 45150.53% in 2025.
- Novavax's EBIAT (Quarter) stood at -$846.3 million in 2021, then skyrocketed by 78.46% to -$182.2 million in 2022, then increased by 2.12% to -$178.4 million in 2023, then skyrocketed by 54.58% to -$81.0 million in 2024, then crashed by 149.76% to -$202.4 million in 2025.
- Its EBIAT was -$202.4 million in Q3 2025, compared to $106.5 million in Q2 2025 and $518.6 million in Q1 2025.